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A B S T R A C T
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow
of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with
rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had
completed autologous stem cell transplantation (ASCT) and in whom an MRDmarker had been obtained were
included in our analysis. Fresh samples of bone marrowwere analyzed for MRD by a combined standard nested
and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-
rangements. Signiﬁcantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated
for patients who were MRD positive pre-ASCT (54 patients) or in the ﬁrst analysis post-ASCT (23 patients).
The median PFS was only 20 months in those who were MRD-positive in the ﬁrst sample post-ASCT, com-
pared with 142 months in the MRD-negative group (P < .0001). OS was 75% at 10 years and median not reached
in the MRD-negative group, compared with only 35 months in the MRD-positive group (P < .0001). Of the 86
patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after
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10 years. For all patients, the median time from ASCT to ﬁrst molecular relapse was 55 months, with a
continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received
rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from ﬁrst
molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD
negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate
analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status
pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients
to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select
some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients
in the ﬁrst analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
High-dose therapy with autologous stem cell transplanta-
tion (ASCT) as consolidationafterﬁrst-line immunochemotherapy
is considered by many to be the preferred ﬁrst-line treatment
for the majority of younger patients with mantle cell lym-
phoma (MCL) [1]. This strategy has led to greatly improved
outcomes for patientswithMCLover the last 10 to 15years [2-5].
Not all patients may beneﬁt from such an aggressive approach,
however. It is well known that amore indolent subtype of MCL
with nonnodal, leukemic disease and absence of SOX11 has a
more favorable prognosis [6]. Low-riskMCL, asmeasured by the
Mantle Cell Lymphoma International Prognostic Index (MIPI), and
lowKi-67 proliferative index have better outcome,whereas high
MIPI score, elevated Ki-67 proliferative index, and/or blastoid
morphology indicatemore aggressive disease, early relapse, and
inferior survival [7,8].
Monitoring of minimal residual disease (MRD) has proven
to be of relevance in patients withMCL to evaluate the quality
of remission and predict clinical relapse [4,9-11]. Thus, the
Nordic MCL2 and MCL3 trials included efforts to reverse mo-
lecular relapse and delay clinical relapse by administering
rituximab as a so-called preemptive strategy [4,11,12], as
opposed to rituximabmaintenance therapy, a strategy thatwas
later found to prolong progression-free survival (PFS) in elderly
patients after conventional immunochemotherapy [13], as well
as after ASCT in younger patients [14]. Herewe report the long-
term results from systematicMRDmonitoring and preemptive
rituximab treatment in the Nordic MCL2 and MCL3 studies.
PATIENTS AND METHODS
Study Population and Treatment
A total of 183 patients included in the Nordic MCL2 andMCL3 trials who
had completed ASCT and in whom a PCR marker for MRD had been ob-
tained were included in our present analysis [4,11]. Both protocols were
approved byMedical Agencies and Ethics Committees, and informed consent
was obtained for each patient. All diagnoses of MCL had been conﬁrmed by
central pathology review. Staging included computed tomography (CT) scans
and bone marrow (BM) aspiration and biopsy. Clinical and molecular re-
sponse evaluationwas performed pre-ASCT and at 2 to 3months, at 6months,
and then every 6 months post-ASCT, until relapse or completion of 5 years
of follow-up. Details on the Nordic MCL treatment regimens have been out-
lined previously [4,11]. In brief, in the Nordic MCL2 trial, patients received
a total of 6 cycles of alternating maxi-CHOP-R (cyclophosphamide,
doxorubicine, vincristine, rituximab, prednisolone, and R-Ara-C [cytarabine,
rituximab]), followed by ASCT. In the NordicMCL3 trial, the induction regimen
remained unchanged, but responding patients not in complete remission
before ASCT received yttium-90 ibritumomab tiuxetan. Treatment outcome
with regard to overall survival (OS), event-free survival (EFS), and PFS, as
well as adverse events, were similar in the MCL2 and MCL3 trials [11]. Pa-
tients who developed a solely molecular relapse during follow-up in both
studies received 4 weekly doses of rituximab (375 mg/m2). This treatment
could be repeated in case of recurrent molecular relapses.
PCR Analysis for MRD
Fresh samples of peripheral blood (PB) and BM were analyzed at the
central laboratory in Copenhagen. DNA was extracted with the QIAprep
Miniprep Kit (Qiagen, Valencia, CA) and used for PCR primer design. The DNA
content was determined by spectrophotometry. A combined standard nested
and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain
gene (IgH) and clonal IgH rearrangements was used to estimate MRD in-
volvement in consecutive post-ASCT BM/PB samples as described in detail
in previous reports [4,12]. BM samples were more sensitive for detection
of MRD; thus, in the present analysis, we used MRD data only from BM.
Eligibility for Preemptive Treatment
The deﬁnition of molecular relapse after ASCT was based on 2 sets of
criteria. When the ﬁrst post-transplantation BM sample was standard nested
PCR-negative, a conversion to standard nested PCR-positive in any subse-
quent BM sample was deﬁned as a molecular relapse. When the ﬁrst post-
transplantation BM sample was standard nested PCR-positive, we awaited
the subsequent BM sample. If this sample was also standard nested PCR-
positive, then we proceeded to real-time quantitative PCR analysis of these
2 consecutive samples. A signiﬁcant (>5-fold) increase in the real-time quan-
titative PCR detectable MRD level was deﬁned as a molecular relapse. PCR-
positive follow-up samples were sequenced to secure identity with the
original IGHV/t(11;14) sequence. Preemptive treatment with 4 weekly doses
of rituximab should be followed by a subsequent MRD analysis. The median
time from preemptive therapy until the next MRD testing was 2 months.
Endpoints and Statistics
PFS was calculated from the date of ASCT or date of molecular relapse
until the date of clinical relapse or progression, death from lymphoma, or
date of last clinical follow-up. Time to molecular progression was calcu-
lated from date of ASCT until ﬁrst molecular relapse or the date of the last
MRD-negative molecular follow-up. OS was deﬁned as the time from ASCT
to death from any cause or the last date of follow-up. Survival analysis was
performed according to the Kaplan-Meier method [15], and differences
between subgroups were analyzed using the log-rank test. The association
between prognostic factors and outcomes was evaluated using a Cox pro-
portional hazards model. The MIPI and MIPI-combined (MIPI-C) were
calculated according to the approach of Hoster et al. [7,16,17].
RESULTS
Outcomes Relative to MRD Status Pre- and Post-ASCT
An MRD marker for Bcl-1 or IgH rearrangement was ob-
tained in 215 patients, including 94 of the 160 patients (59%)
in the MCL2 trial and 121 of the 160 patients (76%) in the
subsequent MCL3 trial. Of these, 183 patients who com-
pleted ASCT were included in our present analysis, with a
median follow-up of 8.5 years among survivors. A ﬂow chart
showing outcomes for all patients in this study is presented
in Figure 1. Patients’ characteristics are shown in Table 1. PFS
and OS for the 183 patients recruited were not signiﬁcantly
different from those of the 97 patients who also completed
ASCT and in whom no MRD marker was obtained (data not
shown). Pre-ASCT, 54 patients (42%) were MRD-positive. Both
PFS and OS were signiﬁcantly shorter in these patients than
in the MRD-negative patients, for whommedian PFS had not
been reached (Figure 2A, B). In the ﬁrst sample post-ASCT,
only 23 (13%) of were still MRD-positive. The median PFS was
only 20 months in this group, compared with 142 months
in the MRD-negative group (Figure 2C). This translated into
a signiﬁcantly longer OS in the MRD-negative patients of 75%
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at 10 years andmedian not reached, compared with amedian
OS of only 35 months in the MRD-positive group (P < .0001)
(Figure 2D).
Risk of Clinical Relapse after Molecular Relapse
For all 183 patients, the median time from ASCT to ﬁrst
molecular relapse was 55 months (Figure 3). Sixty-seven pa-
tients were eligible for preemptive rituximab, and 58 received
this therapy as planned. The median time from ﬁrst molec-
ular relapse until clinical relapse for this groupwas 55months
(Figure 4A). Eighty-six of the 183 patients (47%) remained
MRD-negative in all analyses performed after ASCT. Of these,
63 (73%) are still alive and in clinical remission after a median
follow-up of 8.5 years (Figure 4B), whereas 19 (22%) re-
lapsed clinically and 4 died from other causes. In contrast,
of the 97 patients (53%) who were MRD-positive at any time
post-ASCT, 64 (66%) also relapsed clinically. In 27 patients,
this occurred simultaneously or within 3 months after the
molecular relapse, and the majority did not receive preemp-
tive rituximab. Importantly, there were no signs of plateaus
on the curves for time to molecular progression in this cohort
of younger MCL patients treated up front with intensive
immunochemotherapy followed by ASCT and subsequent pre-
emptive rituximab. No serious adverse events were reported
for the patients treated with rituximab based on this MRD-
guided approach.
Outcomes after Preemptive Rituximab Treatment
The outcomes after preemptive rituximab therapy for 28
patients in continuous remission (48%) and 30 patients who
experienced clinical relapse (52%) are shown in Figure 5A, B.
Twenty-ﬁve patients (43%) received rituximab for molecu-
lar relapse onmultiple occasions. Out of a total of 92 rituximab
treatments in which subsequent samples for MRD were ob-
tained, 80 (87%) of led to MRD negativity. Among all of the
rituximab-treated patients who converted to MRD negativ-
ity, 34 (69%) became MRD-positive again in a subsequent
sample, suggesting that rituximab had only a temporary effect.
Typically, patients who experienced a clinical relapse had a
shorter duration of molecular remission after preemptive
treatment (Figure 5B) compared with those who remained
in clinical remission during follow-up (Figure 5A). More-
over, molecular relapse often coincided with clinical relapse
in this group.
Predictors for Molecular Relapse
We further investigated whether the MIPI and MIPI-C,
known clinical prognosticators, could predict molecular
relapse in our patient cohort (Figure 6). Patients catego-
rized as high risk by the MIPI and MIPI-C had signiﬁcantly
shorter time to molecular progression (25 months and 19
months) compared with the lower-risk groups (Figure 6A, B;
P < .0001). On multivariate analysis (Table 2), signiﬁcant pre-
dictors for molecular relapse were MIPI high risk at diagnosis
(hazard ratio, 1.908; 95% conﬁdence interval, 1.368 to 2.661;
P = .0001) and detection of MRD before ASCT (hazard ratio,
2.465; 95% conﬁdence interval, 1.486 to 4.090; P = .0005). Nev-
ertheless, even patients at low risk and those whowereMRD-
negative pre-ASCT continued to becomeMRD-positive during
follow-up.
DISCUSSION
In the present study, we aimed to investigate in detail the
kinetics and consequences of molecular relapses after ASCT
with long-term follow-up inMCL. In linewith previous reports
[9,18], we demonstrated that molecular monitoring is fea-
sible and provides valuable information on the quality of
remission and risk of clinical relapse. The subgroup of pa-
tients who were MRD-positive in the ﬁrst sample post-
ASCT had particularly poor outcomes. Systematic preemptive
treatment of molecular relapses with single-agent rituximab
therapy converted most patients to MRD negativity, and this
procedure could be repeated successfully. Most likely this
postponed clinical relapse; however, given that those results
were uncontrolled, the clinical beneﬁt can be assessed only
indirectly.
Figure 1. Flow chart with outcomes for all 183 patients in the MRD study.
Table 1
Characteristics of the 183 Patients Followed for MRD
Variable Category Value
Male sex, n (%) 140 (77)
Age, yr, median (range) 57 (28-65)
Stage IV, n (%) 170 (93)
MIPI score (n = 182), n (%) Low 83 (46)
Intermediate 59 (32)
High 40 (22)
MIPI C score (n = 156), n (%) Low 58 (37)
Low/intermediate 44 (28)
High/intermediate 33 (21)
High 21 (13)
Cytology (n = 182), n (%) Common 151 (83)
Blastoid 31 (17)
% Ki-67 (n = 157), n (%) 0-29 98 (63)
≥30 59 (38)
MRD indicates minimal residual disease; MIPI, Mantle Cell Lymphoma In-
ternational Prognostic Index.
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As data from long-term follow-up of patients receiving
modern intensive immunochemotherapy and ASCT continue
to emerge, a consistent picture of late recurrence has been
well documented by us and others [19-21]. In parallel, we
observed a continuous pattern of MRD relapses that did not
subside even after 5 to 10 years and included all risk groups.
Therefore, with present therapies, MCL remains incurable, and
novel approaches are needed [22]. Prognostic models for MCL,
the clinical MIPI [7], and the biological MIPI-B [17] that include
the proliferation marker Ki-67 assign patients to high-,
intermediate-, and low-risk groups. Recently, a modiﬁed com-
bination of Ki-67 andMIPI (MIPI-C) was shown to be superior
to MIPI and MIPI-B for risk stratiﬁcation in cohorts from the
European MCL Younger and MCL Elderly trials [16]. We ob-
served that high-risk patients so categorized based on theMIPI
andMIPI-C had a signiﬁcantly shorter time from ASCT to mo-
lecular relapse; however, there was no clear separation
between curves for other risk groups with respect to time to
molecular progression.
In previous studies, we and other demonstrated the ability
of rituximab to induce effective clearance of MRD in MCL
[12,23,24]. The present series is the largest prospective study
to investigate the preemptive strategy with prolonged mo-
lecular and clinical follow-up in patients with MCL. The
median time from molecular relapse until clinical relapse
in 58 patients who received rituximab was as long as 55
months, and a subgroup (48%) was still in clinical remission
at the end of follow-up. Despite the clear evidence that the
preemptive strategy can repeatedly reduce the tumor load
in the bone marrow to below the detection limit of sensi-
tive PCR, and the prolonged time to clinical relapse in treated
patients, the data do not strictly document a clinical beneﬁt
of the preemptive strategy. Only a randomized trial can
resolve this issue.
The high rate of MRD recurrence observed after rituximab
therapy in our trial, and thus the need to repeat the preemp-
tive strategy, supports a more continuous approach like
maintenance rituximab administered every 2 to 3 months,
Figure 2. PFS and OS relative to MRD status before and after ASCT.
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which has been tested in 2 randomized trials. The European
Mantle Cell Lymphoma Network Elderly trial showed signif-
icant improvements in both PFS and OS following R-CHOP
[13], and the LyMa Study in younger patients following ASCT
showed improved EFS and PFS in the maintenance arm [14].
MRD-guided maintenance initiated only after molecular
relapse rather than in all patients may be an option. Alter-
natively, other treatments like lenalidomide, bortezomib, or
novel targeted therapies (eg, ibrutinib, venetoclax) may be
more effective in maintaining stable molecular remission and
thereby preventing clinical relapse.
In line with a previous report [25], another category of pa-
tients at elevated risk for MRD relapse and clinical relapse
in our trial was the pre-ASCT MRD-positive group. These pa-
tients also could potentially beneﬁt from maintenance
rituximab therapy. Another possible strategy for this group
would be to provide additional treatment before ASCT to
achieve MRD-negative status before continuing to transplan-
tation or to consider allogeneic stem cell transplantation
instead of ASCT. The question of whether patients who are
MRD-negative before ASCT really require ASCT is also rele-
vant. A signiﬁcant proportion of patients (47%) remained
MRD-negative in all analyses during long-term follow-up, and
the PFS for this groupwas very favorable. Observationwithout
further intervention might be a reasonable strategy for this
subgroup. Thirteen percent of patients were not in molecu-
lar remission at the ﬁrst analysis post-ASCT, and for this group
the prognosis was dismal, with a high rate of early recur-
rence and short survival. It is unlikely that single-agent
rituximabwould signiﬁcantly improve outcomes in these very
aggressive cases, and other treatments should be consid-
ered, such as allogeneic stem cell transplantation in younger
ﬁt patients or novel targeted therapies.
Technically, to extend the application of MRD monitor-
ing, a mandatory lymph node biopsy or extended Bcl-1 and
IgH primer design would be important to increase the pro-
portion of patients with amolecularmarker [26]. Furthermore,
novel approaches like next-generation sequencing (NGS) and
droplet digital PCR (ddPCR) are currently being explored as
an alternative to quantitative PCR in patients with hemato-
logic malignancies [27-29]. Even though results in MCL have
been encouraging so far, NGS has the disadvantage of high
costs and this methodology is not broadly available at present.
This might be changing with the increases in commercially
available sequencing. The ddPCR method is less labor-
intensive than quantitative PCR in bypassing the use of
dilution-based standard curves, and results in MCL are prom-
ising with sensitivity and reproducibility at least comparable
to those of quantitative PCR [29]. However, until further
studies conﬁrm these ﬁndings, quantitative PCR remains the
standard technique for MRD monitoring in MCL. Impor-
tantly, adherence to the Euro-MRD guidelines [30] for MRD
analysis ensures reliability and standardization across
laboratories.
Figure 3. Proportion of patients free of molecular progression after ASCT.
Figure 4. PFS in patients with molecular relapse (A) or in continuous molecular remission (B) after ASCT.
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In conclusion, in this large prospective study, we conﬁrm
the importance of inducing a molecular remission in MCL.
The continuous pattern of molecular relapse in all risk groups
supports the current view that MCL is incurable. Likewise,
preemptive rituximab treatment of MRD relapse reinduced
molecular remission, but in many cases this remission was
not durable. Therefore, maintenance rituximab may be a
preferred strategy to keep patients in stable molecular
Figure 5. Patients treated with preemptive rituximab for solely molecular relapse.
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remission and delay clinical relapse. MRD monitoring has
the potential to become a useful tool for identifying pa-
tients who should receive interventions aimed to prolong
clinical remission and to spare a signiﬁcant proportion of
patients from unnecessary treatment. Of particular concern
is the poor prognosis of those who are MRD-positive in the
ﬁrst analysis post-ASCT. For this group, novel strategies are
urgently needed.
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